Panitumumab

Phase 2Withdrawn

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Carcinoid Syndrome

Conditions

Carcinoid Syndrome

Trial Timeline

Jul 1, 2013 → Jul 1, 2013

NCT ID

NCT01172717

About Panitumumab

Panitumumab is a phase 2 stage product being developed by Amgen for Carcinoid Syndrome. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01172717. Target conditions include Carcinoid Syndrome.

What happened to similar drugs?

1 of 9 similar drugs in Carcinoid Syndrome were approved

Approved (1) Terminated (1) Active (7)

🔄Pasireotide + OctreotideNovartisPhase 3

🔄Octreotide + Placebo + EverolimusNovartisPhase 3

❌lanreotide Autogel (somatostatin analogue) + Sandostatin long acting release (LAR) Depot (somatostatin analogue)IpsenPhase 3

✅lanreotide (Autogel formulation)IpsenApproved

🔄Lanreotide + PlaceboIpsenPhase 3

🔄Paltusotine + PlaceboCrinetics PharmaceuticalsPhase 3

🔄Telotristat etiprate + Placebo-matching telotristat etiprateLexicon PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (19)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03311750	Phase 2	Terminated	Mar 26, 2018	May 20, 2021	Advanced Colorectal Cancer
NCT03043950	Pre-clinical	Completed	Jan 25, 2017	Jan 17, 2024	Metastatic Colorectal Cancer
NCT02301962	Approved	UNKNOWN	Jul 28, 2015	Jan 31, 2022	Cancer
NCT01172717	Phase 2	Withdrawn	Jul 1, 2013	Jul 1, 2013	Carcinoid Syndrome
NCT01312493	Phase 2	Withdrawn	Dec 1, 2011	Dec 1, 2018	Head and Neck Cancer
NCT01412957	Phase 3	Completed	Nov 1, 2011	Nov 1, 2016	Metastatic Colorectal Cancer
NCT00984217	Phase 2	Withdrawn	Aug 1, 2011	Aug 1, 2011	Adenoma, Pleomorphic
NCT01296035	Phase 2	Terminated	Feb 1, 2011	Nov 1, 2013	Ovarian Cancer
NCT01305772	Phase 2	Terminated	Jan 1, 2011	May 1, 2012	Squamous Cell Carcinoma of the Head and Neck
NCT01202409	Phase 2	Completed	Nov 2, 2010	Jul 3, 2018	Gastrointestinal Cancer
NCT01175733	Phase 1/2	Completed	Jul 8, 2010	May 1, 2016	Pancreatic Cancer
NCT01128387	Phase 1/2	Terminated	May 1, 2010	Oct 1, 2016	Cancer
NCT01126112	Phase 2	Completed	May 1, 2010	Jul 1, 2014	Colorectal Cancer
NCT00842257	Phase 2	Completed	May 1, 2009	Dec 1, 2011	Colorectal Cancer
NCT00658658	Phase 1	Completed	Mar 1, 2008	Mar 1, 2015	Solid Tumors
NCT00446446	Phase 2	Completed	Oct 30, 2007	Nov 29, 2017	Cancer
NCT00089635	Phase 2	Completed	Aug 1, 2004	Aug 1, 2008	Colorectal Cancer
NCT00083616	Phase 2	Completed	Mar 1, 2004	Dec 1, 2008	Colorectal Cancer
NCT00113763	Phase 3	Completed	Jan 1, 2004	Jun 1, 2009	Colorectal Cancer

Competing Products

20 competing products in Carcinoid Syndrome

See all competitors

Product	Company	Stage	Hype Score
Ramucirumab + Somatostatin Analog	Eli Lilly	Phase 2	35
Pasireotide	Novartis	Phase 1	29
Pasireotide + Octreotide	Novartis	Phase 3	40
Pasireotide (SOM230)	Novartis	Phase 2	35
Octreotide + Placebo + Everolimus	Novartis	Phase 3	40
Lutathera	Novartis	Phase 2	27
EPO906 epothilone B	Novartis	Phase 2	35
Axitinib	Pfizer	Phase 2	35
Lanreotide + Placebo (for sunitinib) + Sunitinib	Pfizer	Phase 2	31
Nivolumab + Cabozantinib	Bristol Myers Squibb	Phase 2	35
bevacizumab + 5-fluorouracil + leucovorin + oxaliplatin	Sanofi	Phase 2/3	30
lanreotide Autogel (somatostatin analogue) + Sandostatin long acting release (LAR) Depot (somatostatin analogue)	Ipsen	Phase 3	29
lanreotide (Autogel formulation)	Ipsen	Approved	40
Lanreotide + Placebo	Ipsen	Phase 3	37
BIM 23A760	Ipsen	Phase 2	24
Randomized: 40 mg Paltusotine + Randomized: 80 mg Paltusotine	Crinetics Pharmaceuticals	Phase 2	32
Paltusotine + Placebo	Crinetics Pharmaceuticals	Phase 3	44
Telotristat etiprate + Placebo-matching telotristat etiprate	Lexicon Pharmaceuticals	Phase 3	34
Telotristat etiprate	Lexicon Pharmaceuticals	Phase 3	34
500 mg [14C]-LX1606	Lexicon Pharmaceuticals	Phase 1	23